0QT6 Stock Chart & Stats
€14.40
-€0.62(-4.54%)
At close: 4:00 PM EDT
€14.40
-€0.62(-4.54%)
Day’s Range― - ―
52-Week Range€3.40 - €15.46
Previous CloseN/A
Volume1.58K
Average Volume (3M)47.10K
Market Cap
€541.90M
Enterprise Value€595.85M
Total Cash (Recent Filing)€113.82M
Total Debt (Recent Filing)€179.28M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Apr 08, 2027EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding50,099,620
10 Day Avg. Volume13,644
30 Day Avg. Volume47,101
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-11.11
Price to Sales (P/S)4.01
P/FCF Ratio-9.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside4.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.11
Revenue Forecast (FY)€81.15M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe sharp 2025 revenue rebound indicates renewed commercial or partnering activity across Genfit’s business and provides a stronger base for future scale. If this growth continues, it could improve operating leverage and support investment in the company’s therapeutic and diagnostic pipeline.
Focused Therapeutic And Diagnostic PlatformGenfit’s focused positioning in metabolic and liver diseases gives its development efforts a coherent strategic direction rather than a broad, unfocused pipeline. Combining treatments with diagnostics may support patient identification and stratification across related disease programs.
Demonstrated Profitability PotentialPositive EBIT, EBITDA, and net income in 2024 demonstrate that Genfit has previously converted its activities into accounting profits. Although 2025 reversed that outcome, the earlier result provides evidence of potential earnings capacity if revenue growth and cost control become more consistent.
Bears Say
Balance-Sheet StressThe shift to negative shareholders’ equity materially weakens Genfit’s financial resilience and reduces flexibility to absorb continued losses. Higher debt adds funding pressure, while the combination of leverage and negative equity may constrain investment in clinical development and increase reliance on external capital.
Renewed Cash BurnNegative operating and free cash flow indicate that the business was not self-funding in 2025 and had to absorb renewed cash consumption. The broader history of several negative-cash-flow years suggests this is a recurring sustainability issue rather than an isolated period of investment.
Unstable ProfitabilityThe disconnect between strong revenue growth and a return to large operating and net losses shows that top-line expansion has not yet translated into durable profitability. Earnings have also varied sharply across years, reducing confidence in predictable margins and long-term earnings conversion.
Genfit News
0QT6 FAQ
What was Genfit SA’s price range in the past 12 months?
Genfit SA lowest share price was €3.40 and its highest was €15.46 in the past 12 months.
What is Genfit SA’s market cap?
Genfit SA’s market cap is €541.90M.
When is Genfit SA’s upcoming earnings report date?
Genfit SA’s upcoming earnings report date is Apr 08, 2027 which is in 159 days.
How were Genfit SA’s earnings last quarter?
Genfit SA released its earnings results on Sep 28, 2026. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of -€0.16 by -€0.04.
Is Genfit SA overvalued?
According to Wall Street analysts Genfit SA’s price is currently Undervalued.
Does Genfit SA pay dividends?
Genfit SA does not currently pay dividends.
What is Genfit SA’s EPS estimate?
Genfit SA’s EPS estimate is -0.37.
How many shares outstanding does Genfit SA have?
Genfit SA has 50,099,620 shares outstanding.
What happened to Genfit SA’s price movement after its last earnings report?
Genfit SA reported an EPS of -€0.2 in its last earnings report, missing expectations of -€0.16. Following the earnings report the stock price went up 9.54%.
Which hedge fund is a major shareholder of Genfit SA?
Currently, no hedge funds are holding shares in GB:0QT6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genfit SA
Genfit S.A. operates as a biopharmaceutical enterprise, concentrating its efforts on discovering and developing both therapeutic candidates and diagnostic solutions for metabolic and liver-related ailments. Its current pipeline includes Elafibranor, which is progressing through Phase 3 clinical trials for the treatment of primary biliary cholangitis (PBC). The firm is additionally engaged in advancing the NIS4 technology, designed for the accurate diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis. Other investigational treatments comprise GNS561, currently in Phase 1b/2 trials for cholangiocarcinoma (CCA), and Nitazoxanide, undergoing Phase 1 evaluation for acute-on-chronic liver failure. Genfit has established key partnerships, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a molecular diagnostic test leveraging blood samples. Furthermore, it collaborates with Genoscience Pharma on the development and market launch of the experimental CCA therapy, GNS561. Established in 1999, Genfit S.A. maintains its headquarters in Loos, France.
0QT6 Stock 12 Month Forecast
Average Price Target
€15.00
▲(4.17% Upside)